GSK Wary Of Flonase Generic Surprise; Asks FDA For Notice
Executive Summary
GlaxoSmithKline is asking FDA for a three-day stay of action once the agency notifies the company of its decision to grant final approval for generic versions of its nasal steroids Flonase and Beconase AQ
You may also be interested in...
FDA Approves Generic Of GSK Flonase But Launch Halted By Restraining Order
FDA's approval of generic Flonase has prompted a lawsuit by GlaxoSmithKline representing another challenge by brand manufacturers to the legitimacy of FDA-approved generic drugs
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011